» Articles » PMID: 34667568

Photoprocesses of the Tyrosine Kinase Inhibitor Gefitinib: from Femtoseconds to Microseconds and from Solution to Cells

Overview
Journal Chem Sci
Specialty Chemistry
Date 2021 Oct 20
PMID 34667568
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Gefitinib (GFT) is a tyrosine kinase inhibitor currently used for the treatment of metastatic non-small cell lung cancer. Although it has been suggested that GFT can be phototoxic, there are no systematic studies on this issue. Here, the photosensitizing potential of GFT has been assessed by means of NRU assays and protein photooxidation. In addition, a thorough photophysical study is presented based on ultrafast transient absorption spectroscopy, fluorescence and laser flash photolysis. Transient species generated after excitation of GFT have been characterized in solution and in biological environments ( HSA and HaCaT cells) to gain insight into the mechanisms involved in photodamage. The photobehavior of GFT was strongly medium-dependent. Excitation of the drug resulted in the formation of locally excited (LE) singlet states (GFT*), which were found to be the main emissive species in non-polar solvents and also within HSA and HaCaT cells. By contrast, in polar solvents, LE states rapidly evolved (∼1 ps) towards the formation of longer-lived intramolecular charge transfer (ICT) states. The triplet excited state of GFT (GFT*) can be formed through intersystem crossing from GFT* in non-polar solvents and from ICT states in the polar ones, or in the particular case of ethanol, by photosensitization using 2-methoxyacetophenone as an energy donor. In the HSA environment, GFT* was hardly detected due to quenching of its LE GFT* precursor by Trp through an electron transfer process. Accordingly, HSA photooxidation by GFT was demonstrated using the protein carbonylation method. In summary, a good correlation is established between the photophysical behavior and the photobiological properties of GFT, which provides a mechanistic basis for the observed phototoxicity.

Citing Articles

Modulation of the photobehavior of gefitinib and its phenolic metabolites by human transport proteins.

Tamarit L, El Ouardi M, Lence E, Andreu I, Gonzalez-Bello C, Miranda M Front Pharmacol. 2024; 15:1387057.

PMID: 38818381 PMC: 11137198. DOI: 10.3389/fphar.2024.1387057.


Cellular photo(geno)toxicity of gefitinib after biotransformation.

El Ouardi M, Tamarit L, Vaya I, Miranda M, Andreu I Front Pharmacol. 2023; 14:1208075.

PMID: 37351506 PMC: 10283009. DOI: 10.3389/fphar.2023.1208075.


Switching from ultrafast electron transfer to proton transfer in excited drug-protein complexes upon biotransformation.

Tamarit L, El Ouardi M, Lence E, Andreu I, Gonzalez-Bello C, Vaya I Chem Sci. 2022; 13(33):9644-9654.

PMID: 36091919 PMC: 9400592. DOI: 10.1039/d2sc03257k.

References
1.
Vaya I, Jimenez M, Miranda M . Excited-state interactions in flurbiprofen-tryptophan dyads. J Phys Chem B. 2007; 111(31):9363-71. DOI: 10.1021/jp071301z. View

2.
Wieduwilt M, Moasser M . The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008; 65(10):1566-84. PMC: 3060045. DOI: 10.1007/s00018-008-7440-8. View

3.
Mendelsohn J, Baselga J . The EGF receptor family as targets for cancer therapy. Oncogene. 2001; 19(56):6550-65. DOI: 10.1038/sj.onc.1204082. View

4.
Foote C . Definition of type I and type II photosensitized oxidation. Photochem Photobiol. 1991; 54(5):659. DOI: 10.1111/j.1751-1097.1991.tb02071.x. View

5.
Vaya I, Bonancia P, Jimenez M, Markovitsi D, Gustavsson T, Miranda M . Excited state interactions between flurbiprofen and tryptophan in drug-protein complexes and in model dyads. Fluorescence studies from the femtosecond to the nanosecond time domains. Phys Chem Chem Phys. 2013; 15(13):4727-34. DOI: 10.1039/c3cp43847c. View